Study of urinary proteomes in Anderson-Fabry disease

Renal Failure

Volumn 32, Issue 10, 2010, Pages 1202-1209

  Vojtová, Lucie ^a   Zima, Tomáš ^a   Tesař, Vladimír ^a   Michalová, Jana ^b   Přikryl, Petr ^b   Dostálová, Gabriela ^a   Linhart, Aleš ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Anderson Fabry disease; MALDI TOF MS; Two dimensional electrophoresis; Urinary proteomes

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 1 MICROGLOBULIN; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C1Q; IMMUNOGLOBULIN KAPPA CHAIN; PROSTAGLANDIN D SYNTHASE; PROTEOME; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROPHORESIS; FABRY DISEASE; FEMALE; HUMAN; ISOELECTRIC FOCUSING; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN GLYCOSYLATION; PROTEIN SECRETION; PROTEIN URINE LEVEL; PROTEOMICS; SILVER STAINING; TWO DIMENSIONAL GEL ELECTROPHORESIS; URINALYSIS;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FABRY DISEASE; FEMALE; GLYCOSYLATION; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; ISOELECTRIC FOCUSING; LIPOCALINS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; PROTEINS; PROTEOME; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; YOUNG ADULT;

EID: 77958160704     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2010.516859     Document Type: Article

References (32)

1. Beck M, Ricci R, Widmer U, et al. Fabry disease: Overall effects of agalsidase alfa treatment. Eur J Clin Invest. 2004;34:838-844.
2. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34:236-242.
3. Elleder M. Sequelae of storage in Fabry disease-pathology and comparison with other lysosomal storage diseases. Acta Paediatr Suppl. 2003;92:46-53.
4. Linhart A, Palecek T, Bultas J, et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J. 2000;139:1101-1108.
5. Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart. 2007;93:528-535.
6. Tesar V, Zima T, Kalousová M. Pathobiochemistry of nephrotic syndrome. Adv Clin Chem. 2003;37:173-218.
7. Schiffmann R, Murray GJ, Treco D, et al. Infusion of α- galactosidase A reduces tissue globotriaozylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA. 2000;97:365-370.
8. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79:31-40.
9. MecDermot J, Holmes A, Miners A. Anderson-Fabry disease: Clinical manifestations in a cohort of 60 obligate carrier females. J Med Genet. 2001;38:769-775.
10. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human α-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med. 2001;345:9-16.
11. Schiffmann R, Kopp JB, Austin HA. Enzyme replacement therapy in Fabry disease: A randomized controlled trial. J Am Med Assoc. 2001;285:2743-2749.
12. Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: A randomized trial. Ann Intern Med. 2007;146:77-86.
13. Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA. 2008;105(8):2812-2817.
14. Schiffmann R, Waldek S, Benigni A, Auray-Blais Ch. Biomarkers of Fabry disease nephropathy. Clin J Am Soc Nephrol. 2010;5(2):360-364.
15. Vojtová L, Zima T, Tesar V, Kazderová M. Study of urinary proteomes in patients with nephrotic syndrome. Folia Biol (Praha). 2007;53(2):58-65.
16. Cutillas PR, Chalkley RJ, Hansen KC, et al. The urinary proteome in Fanconi syndrome implies specificity in the reabsorption of proteins by renal proximal tubule cells. Am J Physiol Renal Physiol. 2004;287: F353-F364.
17. Pieper R, Gatlin ChL, McGrath AM. Characterization of the human urinary proteome A method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics. 2004;4:1159-1174.
18. Rossing K, Mischak H, Parving H-H. Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney Int. 2005;68:193-205.
19. Joo W-A, Lee D-Y, Kim Ch-W. Development of an effective sample preparation method for the proteome analysis of body fluids using 2-D gel electrophoresis. Biosci Biotechnol Bioc hem. 2003;67:1574-1577.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248.
21. Watanabe N, Kamei S, Ohkubo A. Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. Clin Chem. 1986;32:1551-1554.
22. Kleinbaum DG, Kupper CL, Muller KF. Applied Regression Analysis and Other Multivariable Methods. Boston: PWS-Kent; 1988.
23. Dean KJ, Sung SS, Sweeley CC. The identification of alpha-galactosidase B from human liver as an alpha-N-acetylgalactosaminidase. Biochem Biophys Res Commun. 1977;77(4):1411-1417.
24. Ogawa M, Hirawa N, Tsuchida T. Urinary excretions of lipocalin-type prostaglandin D2 synthase predict the development of proteinuria and renal injury in OLETF rats. Nephrol Dial Transplant. 2005;21:924-934.
25. Oda H, Shiina Y, Seiki K. Development and evaluation of a practical ELISA for human urinary lipocalin-type prostaglandin D synthase. Clin Chem. 2002;48:1445-1453.
26. Tsuchida T, Eguchi N, Eguchi Y. Lipocalin-type prostaglandin D synthase in urine in adriamycin-induced nephropathy of mice. Nephrol Physiol. 2004;96:42-51.
27. Tesar V, Zima T. Recent progress in pathogenesis of nephrotic proteinuria. Crit Rev Clin Lab Sci. 2008;45:139-220.
28. Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev. 2008;88:451-487.
29. Vilasi A, Cutillas PR, Maher AD. Combined proteomic and metabonomic studies in three genetic forms of the renal Fanconi syndrome. Am J Physiol Renal Physiol. 2007;293:456-467.
30. 3) in patients with Fabry disease. Clin Chem Acta. 1999;279:55-68.
31. Moran V, Obrador GT, Thandahi R. Fabry kidney disease. Saudi J Kidney Dis Transpl. 2003;14(1):367-377.
32. Ortiz A, Oliviera JP, Waldek S. Nephropathy in males and females with Fabry disease: Cross-sectional description of patients before treatment with enzymereplacement therapy. Nephrol Dial Transplant. 2008;23:1600-1607.